Bell Watch: Low Float Nasdaq Breakout Idea (INBS) Has 10+ Triggered Technicals, 5 Potential Catalysts Overall

Tuesday's opening bell will be here before you know it, so let's dive in quickly.

*Sponsored StockWireNews Bell Watch: Low Float Nasdaq Breakout Idea (INBS) Has 10+ Triggered Technicals, 5 Potential Catalysts Overall March 25th Greetings Readers, Tuesday's opening bell will be here before you know it, so let's dive in quickly. Right now, I'm bringing a little-known company starting to make some serious waves across the globe. And though it may be little-known now, it's starting to trend in the opposite direction. Why? How about 2 key partnerships announced since the start of 2025 helping expansion efforts across Europe and the Middle East. Bullish technical indicators? Barchart is reporting them. In fact, in the afternoon Monday, there were 10+ triggered overall. A low float? Yahoo Finance reports roughly 5.17Mn shares signaling the potential for heightened volatility. And with the global market for Drug Screening being valued at $12.6Bn in 2024 and projected to reach $31.8Bn by 2030, now may be the perfect time to consider this Nasdaq profile for your radar: *Intelligent Bio Solutions Inc. (Nasdaq: INBS)* Intelligent Bio Solutions Inc. is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including o-piates, co-caine, meth-am-phetamine, and cann-a-bis. And based on multiple potential catalysts, (Nasdaq: INBS) has caught my immediate attention. Take a look: #1. A Low Float Could Create Heightened Volatility In A Flash. #2. A Multitude Of Triggered Technicals Could Generate Breakout Buzz! #3. Financial Results Suggest Company's "Business Model Is Excelling." #4. Key Expansion Underway With Game-Changing UK Partnership. #5. A New Fruitful Partnership Expands Reach Across Europe And The Middle East. But more on those in a second... Pioneering Pain-free Solutions Simpler Drug Testing The company's Intelligent Fingerprinting Drug Screening System is revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields.

Science When we ingest something, our bodies metabolize it to produce secondary chemicals (metabolites) detectable in blood, urine, saliva, and sweat. The metabolites we produce are specific to the substances we have consumed. Drug tests screen for specific drugs and drug metabolites in body fluids. The Intelligent Fingerprinting Drug Screening System detects recent drug misuse by screening for specific drugs or their metabolites in sweat from fingerprints. The detection window for drugs in sweat can vary depending on factors such as the drug's half-life, the individual's metabolism, and the specific testing method. The company's system tests for "fitness for duty" on the day and has a detection window of 16-24 hours. Technology The company's Intelligent Fingerprinting Drug Testing Solution consists of single-use, tamper-proof Drug Screening Cartridges (for sample collection) and the portable DSR-Plus Reader for analysis. The Cartridge uses lateral flow assay technology and fluorescence-labelled antibodies to selectively detect specific drugs or their metabolites in sweat collected from fingerprints. The portable DSR-Plus Reader is a highly sensitive, robust, and effective fluorescence measurement instrument used to read the Drug Screening Cartridge, providing a negative or non-negative result for each drug in the screening test within minutes. The company's screening tests are quick and easy to administer due to the non-invasive sample collection method. Each Cartridge screens for o-piates, meth-am-pheta-mine, co-caine and cann-a-bis.

Intelligent Fingerprinting Platform vs Other Drug Testing Standards

U.S. Market Potential - Addressing A $400 billion Substance Abuse Problem(1) Drug Screening Products Market Segment Size: $14.9Bn by 2030(2) CAGR: 12.1%(2) Key Drivers Stringent regulations and a focus on workplace safety Growth in substance abuse cases Demand for faster, non-invasive testing technologies Opp. for Fingerprint-Based Solutions Aligns with market demand for convenience, speed, and accuracy Poised to disrupt traditional urine and saliva testing methods Pathway To U.S. Commercial Launch

Grab Sources And More: INBS Website. INBS Presentation. ----- And based on multiple potential catalysts mentioned above, (Nasdaq: INBS) has quickly risen the ranks to the top spot on my watchlist. Check them out: #1. INBS Potential Catalyst - A Low Float Could Create Heightened Volatility In A Flash. According to info from the Yahoo Finance website, INBS has a fairly low float. In fact, the website reports this profile to have approx. 5.17Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If the company provides more positive company news in the first half of 2025, could it provide a near term spark? ----- #2. INBS Potential Catalyst - A Multitude Of Triggered Technicals Could Generate Breakout Buzz! On Monday at 1:00PM EST, Barchart was reporting several triggered technical indicators across the short, medium, and long term for INBS. Here's their list (as of 1:00PM EST Monday): Short Term Indicators 20 - 50 Day MA Crossover 20 - 100 Day MA Crossover 20 - 200 Day MA Crossover Medium Term Indicators 50 Day Moving Average 50 - 100 Day MA Crossover 50 - 150 Day MA Crossover 50 - 200 Day MA Crossover Long Term Indicators 100 Day Moving Average 150 Day Moving Average 200 Day Moving Average 100 - 200 Day MA Crossover The website also shares its all-important "Trend Seeker" composite indicator is triggered as well. Make sure to watch these technical indicators closely moving forward. ----- #3. INBS Potential Catalyst - Financial Results Suggest Company's "Business Model Is Excelling." Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements Gross pro-fit increase of 32.6% and 11-point gross pro-fit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-Bn dollar U.S. market in 2025 Added strategic partnerships, increasing visibility across the Asia-Pacific Region and the U.S. Secured 19 accounts during quarter, adding to 400+ active customer accounts in 19 countries NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal second quarter and six months ended December 31, 2024, and provided a business update. "Fiscal Q2 was a successful quarter for the business in a number of areas. From a financial standpoint, our business model is excelling, with higher-margin cartridge sales steadily increasing, contributing to our gross pro-fit and margin growth. Our focus on deal size and growing the volume of cartridge sales has resulted in an 11-point increase in our gross pro-fit margin," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "From a regulatory standpoint, our clinical studies returned strong results, and we achieved a significant milestone with the submission of our FDA 510(k) package in December. We remain on track to enter the multi-Bn dollar U.S. market this year, and look forward to the opp's this will present for the business. In addition, we successfully executed on our international expansion plans, adding key strategic partnerships in the Asia-Pacific Region and the U.S." "Our performance over the first half of fiscal 2025 shows that our focus on growing cartridge sales is translating to higher gross pro-fit and margins. We were pleased that gross pro-fit grew to 32.6% while gross profit margins increased to 38.5% from 27.7% for the six months ended December 31, 2024, year-over-year, showing that we have made strides in sustaining the Company's long-term financial strength," said Spiro Sakiris, CFO at Intelligent Bio Solutions. "We expect cartridge sales to continue outpacing reader sales moving forward, maximizing our recurring revenue. We also continued to scale our customer base of over 400 accounts and expand our international presence, which we expect will continue to grow as we enter the U.S. market this year." ... Read the full article here. ----- #4. INBS Potential Catalyst - Key Expansion Underway With Game-Changing UK Partnership. Intelligent Bio Solutions Expands with UK Partnership, Driving Global Growth Ahead of Planned U.S. Launch Avon Freight Group selects INBS' fingerprint drug testing for three UK sites, reinforcing workplace safety and efficiency INBS surpasses 400+ accounts in 19 countries, targeting aggressive U.S. expansion in 2025 following FDA 510(k) submission UK drug testing market projected to hit $453Mn by 2030, positioning INBS as a scalable, cost-effective industry leader NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Avon Freight Group ("Avon") has selected its non-invasive Intelligent Fingerprinting Drug Testing Solution for random drug testing across its three UK sites, supporting proactive risk management and employee well-being. The addition of Avon further expands INBS' client network of over 400 accounts in 19 countries. ... Martin Bullimore, Commercial & Procurement Contracts Manager at Avon Freight Group, commented, "We've never had an in-house testing solution before, and moving to fingerprint drug testing is a big step forward for us. We recognized the need for a more proactive approach to workplace testing and appreciated the non-invasive nature of this solution. The system allows us to conduct random testing without disrupting operations or imposing on our employees' personal lives and reinforces our commitment to a safe, effective, and respectful workplace. The feedback has been extremely positive overall, with many stakeholders realizing its value." As more businesses in the logistics and transport sector recognize the limitations of traditional drug screening methods, solutions such as INBS' Drug Screening System are increasingly becoming the preferred choice. Market research estimates the UK Drug of Abuse Testing Services Market to be the fastest-growing regional market in Europe, projected to reach $453Mn by 2030. INBS is well-established and positioned to satisfy this growing demand with its scalable and cost-effective solution. ... Read the full article here. ----- #5. INBS Potential Catalyst - A New Fruitful Partnership Expands Reach Across Europe And The Middle East. Intelligent Bio Solutions Partners with IVY Diagnostics to Expand in Europe's $3.6Bn Drug Screening Market and in Middle Eastern Regions NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the strengthening of its foothold throughout Europe and the Middle East through its partnership with IVY Diagnostics Srl ("IVY Diagnostics"). As a key distributor, IVY Diagnostics is playing an integral role in expanding the adoption of INBS' Intelligent Fingerprinting Drug Testing Solution across Europe and the Middle East, with a particular focus on drug rehabilitation and law enforcement applications. According to Grand View Research, the European and Middle Eastern drug screening markets are projected to grow significantly by 2030, with Europe expected to reach $3.6Bn and the Middle East and Africa $432.7Mn. This growing demand emphasizes the strategic importance of INBS' partnership with IVY Diagnostics. ... As the demand for drug screening solutions rises across Europe and the Middle East, INBS' collaboration with IVY Diagnostics positions the Company to effectively capture new opp's. IVY Diagnostics serves as INBS' primary contact in Europe, leveraging its extensive network of distributors and expertise in identifying and vetting new partners across key regions, including Romania, Hungary, Slovakia, Austria, and Scandinavia. The collaboration extends to the Middle East, targeting markets such as the UAE, Saudi Arabia, and Qatar. "Our strategic partnership with IVY Diagnostics plays a key role in introducing our fingerprint sweat-based drug screening technology to new markets and industries," said Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions. "Their deep understanding of the regulatory landscape, coupled with their extensive connections across Europe and the Middle East, positions them as an invaluable partner in our mission to provide safer and more efficient drug testing solutions worldwide." ... Read the full article here. ----- (Nasdaq: INBS) Recap - 5 Potential Catalysts Lead The Way #1. A Low Float Could Create Heightened Volatility In A Flash. #2. A Multitude Of Triggered Technicals Could Generate Breakout Buzz! #3. Financial Results Suggest Company's "Business Model Is Excelling." #4. Key Expansion Underway With Game-Changing UK Partnership. #5. A New Fruitful Partnership Expands Reach Across Europe And The Middle East. ----- Coverage is officially initiated on Intelligent Bio Solutions Inc. (Nasdaq: INBS). I'll be in touch with updates as the week moves on. Talk again soon. Sincerely, Kai Parker StockWireNews Sources: (1)(2) (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

*StockWireNews.com ("StockWireNews" or "SWN" ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 03/24/2025 and ending on 03/25/2025 to publicly disseminate information about (INBS:US) via digital communications. Under this agreement, SWN Media LLC has been paid fifteen thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (INBS:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/inbs/#details Unsubscribe Stock Wire News 160 West Camino Real Unit 886 Boca Raton, Florida 33432 United States